Cell­tri­on's rheuma­toid arthri­tis drug meets both end­points in PhI­II; New com­pa­ny Tri­bune emerges to take on fi­brot­ic dis­eases

Cell­tri­on Health­care an­nounced pos­i­tive re­sults from its year-long Phase III tri­al of its rheuma­toid arthri­tis drug Yu­fly­ma in pa­tients re­ceiv­ing ther­a­py on Tues­day, as the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER